lunedì, 15 aprile 2024
11 Maggio 2018

FDA Approves Frontline Daratumumab/VMP Combo for Multiple Myeloma

May 8, 2018 – The FDA has approved daratumumab in combination with bortezomib, melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT), based on findings from the ALCYONE study. In the pivotal, open-label phase III study, daratumumab plus VMP demonstrated a 50% reduction in the risk of progression or death compared with VMP alone. The median … (leggi tutto)